Dr. Marty on Letermovir for CMV Prevention After Stem Cell Transplant
Francisco Marty, MD, Dana-Farber Cancer Institute, discusses the initial results of the Phase III trial evaluating letermovir for CMV after bone marrow transplant.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
2 Clarke Drive Cranbury, NJ 08512